Red Flags

OMER — Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's

**THE CORE CONCERN**

The most direct quantitative signal is the Beneish M-Score of −1.03. On this negative scale, the value lies closer to zero than the −1.78 manipulation threshold, placing it in the zone the model associates with elevated probability of earnings manipulation. The same model produced comparable readings for Enron in fiscal 1997–1998. Supporting this reading is a total accruals to total assets (TATA) ratio of 0.346, indicating that accruals constitute more than one-third of the balance sheet. The Altman Z-Score of −1.59 sits inside the distress zone below 1.81. Short interest at 16.4 percent of float and a beta of 2.99 complete a profile in which reported earnings quality and balance-sheet solvency metrics both deviate from historical norms for non-manipulating firms.

**HISTORICAL PRECEDENT**

The combination of an M-Score breach and elevated accruals mirrors the pattern observed at Enron three years before its 2001 collapse, where discretionary accruals and aggressive revenue or cost capitalization produced statistically similar scores. While Omeros operates in biotechnology rather than energy trading, the underlying accounting mechanics—capitalization of development costs, timing of clinical-trial expense recognition, and potential deferral of liabilities—can generate comparable accrual distortions. The absence of any years in which positive net income coincided with negative operating cash flow and the zero cumulative NI–OCF divergence over five years narrow the resemblance to Enron, yet the M-Score and TATA figures still warrant examination of accrual composition.

**WHAT TO VERIFY**

Three items merit direct inspection in the 10-K or 10-Q. First, the composition of the $0.346 TATA figure: how much arises from R&D capitalization, clinical-trial accruals, or changes in accounts payable versus revenue-related accruals. Second, the footnote on going-concern assumptions and any material uncertainties disclosed under ASC 205-40, given the Z-Score placement. Third, the precise inputs to the Beneish model—specifically changes in days’ sales in receivables, gross margin, and asset quality—to isolate whether the −1.03 reading is driven by SGI, AQI, or TATA components.

**COUNTERARGUMENTS**

Biotechnology firms in the pre-commercial phase routinely post negative Z-Scores because they carry large accumulated deficits and limited tangible assets while burning cash on trials. High beta and short interest are also common when binary clinical or regulatory events dominate valuation. The zero NI–OCF divergence and clean accruals ratio of 0.000 suggest that, at the aggregate level, earnings have not outrun cash generation in recent periods. These sector-specific dynamics can produce forensic flags without deliberate manipulation, particularly when revenue remains near zero and most activity is developmental rather than commercial.

VSTM — Verastem, Inc.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade s

**THE CORE CONCERN**

The Beneish M-Score of −1.55 breaches the −1.78 manipulation threshold. On this negative scale the value lies closer to zero than the cutoff, the same zone the model assigned Enron in FY1997–1998. The score is driven primarily by the sales-growth index (SGI) of 3.09, reflecting 209 % year-on-year revenue expansion. Revenue has risen from negligible levels to $0.1 B over three years at a 223 % CAGR. While the accruals ratio sits at 0.000 and cumulative net-income-to-operating-cash-flow divergence is zero, the M-Score still registers above the statistical manipulation line.

**HISTORICAL PRECEDENT**

The combination of an M-Score just inside the manipulation zone and extreme revenue growth mirrors the pattern observed at certain pre-commercial biotechnology firms that later restated revenue or faced SEC inquiries after rapid product launches. In those cases the SGI component alone pushed the model into flagged territory three to five years before cash-flow or restatement evidence surfaced, even when reported accruals remained modest.

**WHAT TO VERIFY**

An investigator should examine three items in the most recent 10-K and 10-Q. First, the precise timing and contractual terms of the revenue recognized in the latest two quarters, including any rights of return or milestone-based arrangements that could accelerate recognition. Second, the allocation of operating cash outflows between R&D, clinical-trial payments, and sales-and-marketing spend to determine whether the cash burn corresponds to documented customer-acquisition or trial-enrollment activity. Third, changes in deferred-revenue and accounts-receivable balances relative to the revenue increase, to assess whether the SGI reflects sustained demand or front-loaded bookings.

**COUNTERARGUMENTS**

Verastem operates in the biotechnology sector and remains pre-profitability, conditions under which both the Altman Z-Score (−0.39) and certain Beneish components routinely produce elevated readings without manipulation. The 223 % revenue CAGR indicates the company is still in an investment phase where legitimate scaling of clinical programs and early commercial infrastructure can generate the same SGI and working-capital patterns the models flag. The zero accruals ratio and absence of any year in which positive net income coincided with negative operating cash flow are consistent with straightforward cash accounting for a development-stage entity rather than earnings management. Short interest at 14.2 % and insider ownership below 1 % are observable market facts but do not, by themselves, confirm or refute the accounting signals.